A-9

Dosage for House Dust allergenic extract is highly individualized and follows a two-phase protocol: the Build-up Phase and the Maintenance Phase. There is no 'standard' dose that applies to all patients.

Build-up Phase (Induction)

During this phase, the patient receives injections once or twice weekly. The starting dose is extremely low, typically a 1:100,000 or 1:10,000 dilution of the maintenance strength. The dose is incrementally increased at each visit (e.g., 0.05 mL, 0.10 mL, 0.20 mL) based on the patient's local reaction and overall tolerance. This phase usually lasts 3 to 6 months.

Maintenance Phase

Once the 'top dose' or maximum tolerated dose is reached, the frequency of injections is decreased to once every 2 to 4 weeks. A common maintenance dose range is 0.2 mL to 0.5 mL of a 1:100 w/v or 1:10 w/v solution, though this varies significantly by manufacturer and patient sensitivity. Maintenance therapy is typically continued for 3 to 5 years to achieve long-lasting desensitization.

House Dust allergenic extract is generally considered safe for use in children, typically starting at age 5. Dosing protocols for children are similar to those for adults, though the physician may exercise more caution during the build-up phase. The decision to start immunotherapy in a child depends on the severity of symptoms and the child's ability to cooperate with frequent injections and the mandatory 30-minute post-injection observation period.

Renal Impairment

No specific dose adjustments are required for patients with renal impairment, as the proteins are not cleared by the kidneys in a manner that would lead to toxicity. However, the patient's overall health must be stable.

Hepatic Impairment

No dosage adjustments are necessary for patients with liver disease. The metabolic pathway of allergenic proteins does not involve hepatic CYP450 enzymes.

Elderly Patients

Caution is advised in elderly patients, primarily due to the increased prevalence of cardiovascular disease. If an elderly patient experiences a systemic reaction (anaphylaxis), they may be less able to tolerate the physiological stress or the administration of epinephrine.

House Dust extract is never self-administered at home. It must be administered by a healthcare professional in a clinical setting (usually an allergist's office) equipped with emergency supplies, including oxygen, IV fluids, and epinephrine.

• Route: Subcutaneous injection (usually in the back of the upper arm).
• Timing: Injections are scheduled during the day when the clinic is fully staffed.
• Observation: You must remain in the doctor's office for at least 30 minutes after every injection to monitor for signs of a systemic allergic reaction.
• Storage: Vials are stored in a refrigerator at 2°C to 8°C (36°F to 46°F). They must not be frozen.

If a dose is missed during the build-up phase, the next dose may need to be reduced or repeated to ensure safety. If a dose is missed during the maintenance phase, the physician will determine the appropriate 'step-back' based on how much time has elapsed since the last injection. Do not attempt to 'double up' on doses.

An 'overdose' in the context of House Dust extract refers to the administration of a dose higher than the patient's current tolerance level. This can lead to a severe systemic allergic reaction (anaphylaxis). Symptoms include:

• Generalized hives (urticaria)
• Swelling of the throat or tongue
• Difficulty breathing or wheezing
• Rapid or weak pulse
• Dizziness or fainting

In the event of an overdose or systemic reaction, epinephrine is the first-line treatment, followed by antihistamines, corticosteroids, and emergency medical support.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most patients undergoing immunotherapy with House Dust extract will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Injection Site Redness (Erythema): The area around the injection may turn red and feel warm. This usually appears within minutes and resolves within 24 hours.
• Local Swelling (Edema): A small bump or 'wheal' at the injection site is common. If the swelling is smaller than the size of a half-dollar (approx. 3 cm), it is usually considered a normal response.
• Itching (Pruritus): Localized itching at the site of the injection is very common and can be managed with topical cold compresses or oral antihistamines.

• Large Local Reactions: Swelling that exceeds 5-10 cm in diameter. While not life-threatening, these often require a dosage adjustment for the next visit.
• Fatigue: Some patients report feeling unusually tired for a few hours following their injection.
• Mild Nasal Congestion: A slight increase in 'hay fever' symptoms shortly after the injection.

• Generalized Urticaria: Hives appearing on parts of the body away from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Persistent Cough: A dry, irritating cough that may signal mild airway narrowing.

> Warning: Stop taking House Dust and call your doctor immediately if you experience any of these. These symptoms may indicate the onset of anaphylaxis, a life-threatening allergic reaction.

• Difficulty Breathing or Wheezing: Indicates bronchospasm (narrowing of the airways).
• Throat Tightness: A feeling that the throat is closing or difficulty swallowing.
• Hypotension (Low Blood Pressure): Feeling faint, dizzy, or suddenly 'lightheaded.'
• Rapid Heartbeat: A racing pulse often accompanied by a sense of impending doom.
• Cyanosis: A bluish tint to the lips or fingernails, indicating lack of oxygen.
• Loss of Consciousness: Fainting or collapse requires immediate emergency intervention.

There are no known long-term 'toxic' effects of House Dust extract on organs like the liver, kidneys, or brain. The primary long-term consideration is the successful modification of the immune system. In rare cases, patients may develop 'serum sickness,' a delayed immune complex reaction characterized by fever, joint pain, and rash, though this is extremely uncommon with modern extracts.

While House Dust extract may not always carry a formal 'Black Box' on every specific manufacturer's label, the FDA requires a General Warning for all allergenic extracts regarding the risk of Severe Systemic Allergic Reactions (Anaphylaxis).

Summary of Warning: House Dust allergenic extract can cause severe, life-threatening systemic reactions, including anaphylaxis. Because of this risk, it must only be administered in a healthcare setting by personnel trained in the management of anaphylaxis. Patients with unstable or severe asthma are at a higher risk for fatal reactions. Patients must be observed for at least 30 minutes following administration.

Report any unusual symptoms to your healthcare provider.

House Dust allergenic extract is a potent biological agent. Its use requires strict adherence to safety protocols to prevent life-threatening complications. Patients must be honest with their providers about their current health status, especially any recent asthma flare-ups or new medications.

No specific FDA black box warning exists for 'House Dust' specifically, but it falls under the class-wide warning for all allergenic extracts: Risk of Systemic Anaphylaxis. This warning emphasizes that the product is not for home use and that patients must be monitored for 30 minutes post-injection due to the risk of sudden, severe allergic collapse.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. The risk is highest during the build-up phase or when starting a new vial (which may be more potent than the previous one).
• Asthma Status: Patients with symptomatic or poorly controlled asthma should not receive a House Dust injection until their asthma is stabilized. A 'peak flow' meter may be used in the office to check lung function before the injection.
• Beta-Blocker Use: Patients taking beta-blockers (for high blood pressure or heart conditions) are at increased risk. Beta-blockers can make anaphylaxis more severe and, more importantly, can make the patient resistant to the effects of epinephrine (the life-saving treatment for anaphylaxis).
• ACE Inhibitors: Some evidence suggests that patients on ACE inhibitors may be at a higher risk for more severe systemic reactions during immunotherapy.

Unlike many drugs, House Dust does not require routine blood work (like liver enzymes or CBC). Monitoring is clinical:

• Pre-Injection Assessment: The nurse or doctor will ask if you had a reaction to the last dose and if you are currently feeling well.
• Post-Injection Observation: A mandatory 30-minute wait in the waiting room.
• Lung Function: For asthmatic patients, periodic spirometry or peak flow monitoring is essential.

House Dust extract does not typically cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a physician.

There is no direct chemical interaction between alcohol and House Dust extract. However, alcohol consumption can cause vasodilation (widening of blood vessels), which may theoretically increase the rate of allergen absorption or mask the early signs of an allergic reaction. It is generally advised to avoid alcohol for several hours after an injection.

Immunotherapy can be stopped at any time without 'withdrawal' symptoms. However, stopping prematurely (before 3 years) often results in the return of allergy symptoms. If you decide to stop, discuss a plan with your allergist.

> Important: Discuss all your medical conditions with your healthcare provider before starting House Dust.

• Non-Selective Beta-Blockers (e.g., Propranolol): These are generally contraindicated in patients receiving House Dust immunotherapy. If the patient experiences anaphylaxis, the beta-blocker prevents epinephrine from working on the heart and airways, potentially leading to a fatal outcome.

• Selective Beta-Blockers (e.g., Atenolol, Metoprolol): While slightly less risky than non-selective versions, they still pose a significant threat during an allergic emergency. Physicians must weigh the benefit of immunotherapy against the cardiac risk.
• ACE Inhibitors (e.g., Lisinopril, Enalapril): These may increase the risk of severe systemic reactions and may interfere with the body's natural compensatory mechanisms during an allergic event.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of epinephrine if it must be administered, leading to dangerously high blood pressure.

• Antihistamines (e.g., Loratadine, Cetirizine): These can interfere with diagnostic skin testing by suppressing the 'wheal and flare' reaction, leading to a false-negative result. Patients must typically stop antihistamines 3 to 7 days before skin testing. During immunotherapy, however, they are often used to manage local side effects.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can alter the body's response to epinephrine.

There are no known direct food interactions with House Dust extract. However, patients should avoid heavy meals or vigorous exercise immediately before and after their injection, as increased body heat and circulation can speed up the absorption of the allergen, increasing the risk of a systemic reaction.

• St. John's Wort: No direct interaction, but patients should inform their doctor of all supplements.
• Ephedra/Ma Huang: Could potentially complicate the cardiovascular response if an allergic emergency occurs.

House Dust extract will not affect standard blood chemistry or hematology tests. However, it will directly affect:

• Skin Prick Tests: Causes a localized allergic reaction (positive result).
• Serum Specific IgE (ImmunoCAP): Patients on immunotherapy will see changes in their dust-specific IgE and IgG4 levels over time, which is the intended clinical effect.

For each major interaction, the mechanism is typically pharmacodynamic (how the drugs affect the body's response) rather than pharmacokinetic (how the body processes the drug). The clinical consequence is almost always related to the management of potential anaphylaxis.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

House Dust extract must NEVER be used in the following circumstances:

1. 1Severe or Uncontrolled Asthma: Patients with a Forced Expiratory Volume in 1 second (FEV1) consistently below 70% of predicted values are at an unacceptably high risk for fatal bronchospasm during a systemic reaction.
2. 2Recent Myocardial Infarction (Heart Attack): Patients with unstable cardiac disease cannot tolerate the physiological stress of anaphylaxis or the administration of epinephrine.
3. 3Hypersensitivity to Preservatives: Most House Dust extracts contain phenol as a preservative. If a patient has a known severe allergy to phenol, the extract is contraindicated.
4. 4Inability to Communicate: Patients who cannot report early symptoms of a reaction (e.g., very young children or those with certain cognitive impairments) may not be suitable candidates.

These conditions require a careful risk-benefit analysis by the allergist:

• Autoimmune Diseases: There is a theoretical risk that stimulating the immune system could worsen conditions like Lupus or Rheumatoid Arthritis, though data is limited.
• Malignancy (Cancer): The effect of immunotherapy on the course of active cancer is unknown.
• Beta-Blocker Therapy: As discussed, this significantly complicates the safety profile.

House Dust extract contains proteins from various sources. Patients allergic to the following may show cross-reactivity:

• Dust Mites: High degree of cross-sensitivity as mites are a primary component of house dust.
• Shellfish: Some patients with dust mite allergies (specifically to the protein tropomyosin) may experience cross-reactivity with shrimp or crab, though this is more relevant for food allergies than for dust injections.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing House Dust.

House Dust allergenic extract is generally classified as FDA Pregnancy Category C. This means there are no adequate and well-controlled studies in pregnant women.

• Induction Phase: It is standard clinical practice not to start House Dust immunotherapy during pregnancy. The risk of a systemic reaction (and the resulting hypoxia to the fetus) outweighs the benefit of starting treatment at that time.
• Maintenance Phase: If a woman is already on a stable maintenance dose and becomes pregnant, the treatment is often continued. The dose is typically not increased during pregnancy to minimize the risk of anaphylaxis.
• Teratogenicity: There is no evidence that allergenic extracts cause birth defects.

It is generally considered safe to continue House Dust immunotherapy while breastfeeding. The allergenic proteins and the resulting antibodies (IgG4) are not known to pass into breast milk in quantities that would adversely affect the nursing infant. In fact, some studies suggest that maternal antibodies in breast milk might have a protective effect on the infant's immune development.

• Approved Age: Use is common in children aged 5 and older.
• Efficacy: Immunotherapy is highly effective in children and may prevent the 'allergic march'—the progression from allergic rhinitis to asthma.
• Special Dosing: While the doses are similar to adults, the physician may use a slower build-up schedule.
• Contraindications: Children under age 5 are often excluded because they may be unable to articulate the early symptoms of a systemic reaction.

Patients over age 65 require careful screening for cardiovascular disease. The primary concern is not the extract itself, but the patient's ability to survive a systemic reaction and the emergency treatments (epinephrine) required. Renal and hepatic clearance changes associated with age do not significantly impact the use of House Dust extracts.

No dosage adjustments are needed. The biological degradation of proteins is independent of renal function. However, if renal failure is part of a multi-organ systemic illness, immunotherapy should be deferred.

No dosage adjustments are needed. The liver's metabolic capacity for drugs does not affect the processing of injected allergenic proteins.

> Important: Special populations require individualized medical assessment.

House Dust extract induces a state of 'immunological tolerance.' The primary molecular targets are T-lymphocytes and B-lymphocytes.

1. 1T-Cell Anergy: High-dose allergen exposure leads to the 'exhaustion' or deletion of allergen-specific Th2 cells.
2. 2Treg Induction: It promotes the differentiation of CD4+CD25+ regulatory T cells, which secrete IL-10. IL-10 is a potent anti-inflammatory cytokine that suppresses IgE production and inhibits mast cell activation.
3. 3B-Cell Switching: IL-10 also signals B-cells to switch production from IgE to IgG4. IgG4 acts as a 'decoy' or 'blocking' antibody.

• Onset of Action: Clinical improvement is not immediate. It typically takes 3 to 6 months (reaching the maintenance dose) to notice a reduction in symptoms.
• Duration of Effect: The goal is permanent modification of the immune system. After a 3-5 year course, many patients remain symptom-free for years after stopping the injections.
• Tolerance: Unlike many drugs where 'tolerance' means the drug stops working, in immunotherapy, 'tolerance' is the desired therapeutic outcome—the body's ability to tolerate environmental dust without an allergic reaction.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous Injection) |

| Protein Binding | N/A (Processed by immune cells) |

| Half-life | Variable (Biological processing takes hours to days) |

| Tmax | Local peak concentration within 1-2 hours |

| Metabolism | Proteolysis by cellular enzymes |

| Excretion | Renal (as peptide fragments) |

• Molecular Formula: N/A (Complex mixture of proteins, polysaccharides, and lipids).
• Molecular Weight: Ranges from 10,000 to 100,000 Daltons for major allergens (e.g., Der p 1, Der f 1).
• Solubility: Soluble in buffered saline solutions.
• Structure: The extract contains globular proteins with specific epitopes (binding sites) that are recognized by IgE antibodies.

House Dust belongs to the Allergenic Extract class. It is further categorized as a Non-Standardized Extract, meaning its potency is determined by its manufacturing process (weight/volume) rather than by a standardized bioassay of specific major allergen content (like the AU/mL used for dust mites).